Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.

Nagakura J, Yamakawa T, Taguri M, Tsuchiya H, Shigematsu E, Suzuki J, Morita S, Kadonosono K, Terauchi Y

Endocrine journal5 Jan 2016Cited by 6 (Europe PMC)

PMID26743240DOI10.1507/endocrj.ej15-0500PepBankPUB-26743240

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, daily glucose fluctuation measured by MAGE did not differ between liraglutide and exenatide.
In plain wordsIn adults with type 2 diabetes, daily blood sugar swings on liraglutide were not different from those on exenatide.
Peptide
Liraglutide
Outcome
No significant changeGlucose fluctuation, MAGE
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Source sentences
Summary
There was no significant between-group difference in glucose fluctuations during the day, as assessed by calculating mean amplitude of glycemic excursion (MAGE) and standard deviation (SD).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324001
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, daily glucose fluctuation measured by SD did not differ between liraglutide and exenatide.
In plain wordsIn adults with type 2 diabetes, daily blood sugar variation on liraglutide was not different from that on exenatide.
Peptide
Liraglutide
Outcome
No significant changeGlucose fluctuation, standard deviation
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Source sentences
Summary
There was no significant between-group difference in glucose fluctuations during the day, as assessed by calculating mean amplitude of glycemic excursion (MAGE) and standard deviation (SD).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324002
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, mean blood glucose 3 hours after breakfast was higher with liraglutide than with exenatide.
In plain wordsIn adults with type 2 diabetes, blood sugar 3 hours after breakfast was higher on liraglutide than on exenatide.
Peptide
Liraglutide
Outcome
IncreaseMean blood glucose 3 hours after breakfast
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Measurements
Mean blood glucose 3 h after breakfast
153.4 mg/dL
liraglutide
Mean blood glucose 3 h after breakfast
127.3 mg/dL
exenatide
Source sentences
Summary
However, the mean blood glucose levels at 3 hours after breakfast and dinner were significantly lower in the exenatide group than the liraglutide group (breakfast: 127.3 ± 24.1 vs. 153.4 ± 28.7 mg/dL; p = 0.006, dinner: 108.7 ± 17.3 vs. 141.9 ± 24.2 mg/dL; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324003
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, mean blood glucose 3 hours after dinner was higher with liraglutide than with exenatide.
In plain wordsIn adults with type 2 diabetes, blood sugar 3 hours after dinner was higher on liraglutide than on exenatide.
Peptide
Liraglutide
Outcome
IncreaseMean blood glucose 3 hours after dinner
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Measurements
Mean blood glucose 3 h after dinner
141.9 mg/dL
liraglutide
Mean blood glucose 3 h after dinner
108.7 mg/dL
exenatide
Source sentences
Summary
However, the mean blood glucose levels at 3 hours after breakfast and dinner were significantly lower in the exenatide group than the liraglutide group (breakfast: 127.3 ± 24.1 vs. 153.4 ± 28.7 mg/dL; p = 0.006, dinner: 108.7 ± 17.3 vs. 141.9 ± 24.2 mg/dL; p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324004
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, average blood glucose between 0000 h and 0600 h was lower with liraglutide than with exenatide.
In plain wordsIn adults with type 2 diabetes, overnight blood sugar was lower on liraglutide than on exenatide.
Peptide
Liraglutide
Outcome
DecreaseAverage blood glucose 0000-0600 h
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Measurements
Average glucose 0000-0600 h
107.1 mg/dL
liraglutide
Average glucose 0000-0600 h
126.9 mg/dL
exenatide
Source sentences
Summary
In contrast, mean blood glucose levels and their SD were significantly lower between 0000 h and 0600 h in the liraglutide group than the exenatide group (average glucose: 126.9 ± 27.1 vs. 107.1 ± 24.0 mg/dL; p = 0.029, SD: 15.2 ± 10.5 vs. 8.7 ± 3.8; p = 0.020).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324005
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on sulfonylureas, the SD of blood glucose between 0000 h and 0600 h was lower with liraglutide than with exenatide.
In plain wordsIn adults with type 2 diabetes, overnight blood sugar varied less on liraglutide than on exenatide.
Peptide
Liraglutide
Outcome
DecreaseBlood glucose SD 0000-0600 h
Study
n = 40
Comparator
Exenatide 10 μg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/dayAs given in this study (human).
Measurements
Glucose SD 0000-0600 h
8.7 mg/dL
liraglutide
Glucose SD 0000-0600 h
15.2 mg/dL
exenatide
Source sentences
Summary
In contrast, mean blood glucose levels and their SD were significantly lower between 0000 h and 0600 h in the liraglutide group than the exenatide group (average glucose: 126.9 ± 27.1 vs. 107.1 ± 24.0 mg/dL; p = 0.029, SD: 15.2 ± 10.5 vs. 8.7 ± 3.8; p = 0.020).
1 context sentence(design, population, supporting numbers)
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324006
07HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, daily mean amplitude of glycemic excursion did not differ significantly between exenatide and liraglutide.
In plain wordsIn type 2 diabetes, daily blood sugar excursion amplitude did not differ significantly between exenatide and liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMean amplitude of glycemic excursion
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Source sentences
Summary
There was no significant between-group difference in glucose fluctuations during the day, as assessed by calculating mean amplitude of glycemic excursion (MAGE) and standard deviation (SD).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324007
08HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, daily glucose standard deviation did not differ significantly between exenatide and liraglutide.
In plain wordsIn type 2 diabetes, daily blood sugar variability did not differ significantly between exenatide and liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDaily glucose standard deviation
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Source sentences
Summary
There was no significant between-group difference in glucose fluctuations during the day, as assessed by calculating mean amplitude of glycemic excursion (MAGE) and standard deviation (SD).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324008
09HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, glucose three hours after breakfast was lower with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, blood sugar after breakfast was lower with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose three hours after breakfast
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Measurements
Mean blood glucose 3 hours after breakfast
127.3 mg/dL
exenatide
Mean blood glucose 3 hours after breakfast
153.4 mg/dL
liraglutide
Source sentences
Summary
However, the mean blood glucose levels at 3 hours after breakfast and dinner were significantly lower in the exenatide group than the liraglutide group (breakfast: 127.3 ± 24.1 vs. 153.4 ± 28.7 mg/dL; p = 0.006, dinner: 108.7 ± 17.3 vs. 141.9 ± 24.2 mg/dL; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324009
10HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, glucose three hours after dinner was lower with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, blood sugar after dinner was lower with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose three hours after dinner
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Measurements
Mean blood glucose 3 hours after dinner
108.7 mg/dL
exenatide
Mean blood glucose 3 hours after dinner
141.9 mg/dL
liraglutide
Source sentences
Summary
However, the mean blood glucose levels at 3 hours after breakfast and dinner were significantly lower in the exenatide group than the liraglutide group (breakfast: 127.3 ± 24.1 vs. 153.4 ± 28.7 mg/dL; p = 0.006, dinner: 108.7 ± 17.3 vs. 141.9 ± 24.2 mg/dL; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324010
11HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, mean glucose between midnight and morning was higher with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, overnight blood sugar was higher with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMean glucose from midnight to morning
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Measurements
Mean blood glucose 0000-0600 h
126.9 mg/dL
exenatide
Mean blood glucose 0000-0600 h
107.1 mg/dL
liraglutide
Source sentences
Summary
In contrast, mean blood glucose levels and their SD were significantly lower between 0000 h and 0600 h in the liraglutide group than the exenatide group (average glucose: 126.9 ± 27.1 vs. 107.1 ± 24.0 mg/dL; p = 0.029, SD: 15.2 ± 10.5 vs. 8.7 ± 3.8; p = 0.020).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324011
12HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, overnight glucose standard deviation was higher with exenatide than liraglutide.
In plain wordsIn type 2 diabetes, overnight blood sugar variability was higher with exenatide than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose standard deviation from midnight to morning
Study
n = 40
Comparator
Liraglutide 0.3-0.9 mg/day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 μg/dayAs given in this study (human).
Measurements
Glucose SD 0000-0600 h
15.2 mg/dL
exenatide
Glucose SD 0000-0600 h
8.7 mg/dL
liraglutide
Source sentences
Summary
In contrast, mean blood glucose levels and their SD were significantly lower between 0000 h and 0600 h in the liraglutide group than the exenatide group (average glucose: 126.9 ± 27.1 vs. 107.1 ± 24.0 mg/dL; p = 0.029, SD: 15.2 ± 10.5 vs. 8.7 ± 3.8; p = 0.020).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the influence of short-term treatment with exenatide twice daily or liraglutide once daily on daily blood glucose fluctuations in 40 patients with type 2 diabetes inadequately controlled by sulfonylureas.
Summary · context
The patients in a multicenter, open-label trial were randomly assigned to receive add-on exenatide (10 μg/day, n = 21) or add-on liraglutide (0.3-0.9 mg/day, n = 19), and underwent 24-hour continuous subcutaneous glucose monitoring.
Report a problemFND-2674324012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.